Vitro Biopharma develops Wharton's jelly of the umbilical cord-derived cell therapies to modulate the immune system and inflammation. Umbilical Cord MSCs are the youngest, most potent adult stem cells known, free from age related issues, prior medical conditions and genetics that come with use of adipose or bone-marrow-derived MSCs. UC-MSCs are significantly superior in multiple categories to other adult stem cells, including the ability to differentiate into neural stem cells (NSCs), adipose and bone-marrow-derived MSCs do not.
Our extensive knowledge of immunology and inflammatory conditions informs our decision making to advance the scientific and clinical path to demonstrate proof-of-concept, with the goal of achieving an efficient timeframe and cost-effective budget.
The mechanisms of action involve immunomodulation that reduces patient immune response to myelin basic protein. Negative regulation of T-cells through secretion of IDO (indolamine dioxygenase) by the conversion of tryptophan to kynurenine that directly inhibits T-cell proliferation. Further MSC-induced up-regulation of TREG cells by TGF-beta secretion from MSCs also suppresses immunity through regulation of dendritic cells. Other mechanisms include cellular repair of demyelination by cellular repair through paracrine effects that repair damaged neurons as evidenced by resolution of plaques by MRI imaging. Anti-inflammatory mechanisms are also likely including MSC-induced shift of M1 pro-inflammatory macrophages to M2 anti-inflammatory macrophages and secretion of PGE2 from MSCs that up-regulates dendritic cells to secrete anti-inflammatory cytokine IL-10 and decrease secretion of pro-inflammatory cytokines TNGF-alpha and IL-12.
Respond to excessive
pro‐inflammatory signals via receptors
for TNF‐α, IFN‐γ and
AlloRx® Stem Cells are derived from the Wharton’s Jelly of the umbilical cord. Cords are ethically sourced and donated after a baby is born. Strict screening of the donor's medical & social history is evaluated as well as rigorous testing of the donor's tissue is preformed prior to accepting cords. The cords are processed in Vitro Biopharma’s ISO 7 cleanroom with strict standard operating procedures and environmental controls. Through Vitro’s proprietary technology, we convert the cells into potential therapeutics by increasing the ATP expression, viability, yield, and has been seen to be more efficacious through different indications. We have a significant cost advantage within our manufacturing process which can derive trillions of cells from one umbilical cord.